M&G plc’s Rhythm Pharmaceuticals RYTM Stock Holding History

M&G plc’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-138,567	Closed	-$12.1M	–	400
2026 Q1	$12.1M	Buy	138,567 +1,493	+1%	+$145K	0.06%	189
2025 Q4	$14.7M	Buy	+137,074	New	+$14.5M	0.08%	157

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

M&G plc's RYTM Position: Q2 2026 in Review

M&G plc sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 138,567 shares — an estimated $12.1M sold.

M&G plc first reported a position in RYTM in Q4 2025 and held it in 2 quarters. The position peaked at $14.7M in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

M&G plc reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
M&G plc sold 138,567 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $12.1M.
M&G plc first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 2 quarters.
M&G plc's Rhythm Pharmaceuticals position peaked at $14.7M in Q4 2025.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.